Platelets News and Research

RSS

Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment

For years, doctors have used platelet-rich plasma, or PRP, to promote healing after surgery. Now, Rush University Medical Center is studying whether PRP can help relieve knee pain in patients with mild to moderate osteoarthritis.

23 Mar 2011

Major breakthrough in thrombosis

Scientists from the University of Reading have announced a major breakthrough in understanding how to control blood clotting which could lead to the development of new treatments and save the lives of thousands of people each year.

17 Mar 2011

Tiniest pollution particles can contribute to cardiovascular disease in diabetic people

Scientists are untangling how the tiniest pollution particles - which we take in with every breath we breathe - affect our health, making people more vulnerable to cardiovascular and respiratory problems.

10 Mar 2011

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Cardium Therapeutics today announced the publication of positive findings from the Company's Matrix Phase 2b clinical study.

9 Mar 2011

Study reveals expansion of NK cells after acute infection

The natural killer cells of our immune defense are activated for an extended period after the acute infection, which challenges the prevailing view that the elevation and activation of cells quickly pass.

3 Mar 2011

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

Oxygen Biotherapeutics, Inc. (NASDAQ and SIX Swiss Exchange: OXBT) today announced it has received a $2,075 million two-year grant from the U.S. Army to study the Company’s proprietary Oxycyte® PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury (TBI).

2 Mar 2011

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

Oxygen Biotherapeutics, Inc. today announced it has received a $2.075 million, two-year grant from the U.S. Army to study the Company's proprietary Oxycyte PFC emulsion as a therapeutic intervention focused on reducing brain damage in victims of traumatic brain injury.

2 Mar 2011

PAH closely related to bone marrow abnormalities

Results from a study published in Blood, the Journal of the American Society of Hematology reveal a close relationship between pulmonary arterial hypertension (PAH)-exceedingly high blood pressure in the arteries carrying blood from the heart to the lungs-and abnormalities of the blood-forming cells in the bone marrow (known as myeloid abnormalities).

1 Mar 2011

Refrigerated whole blood may have shelf life beyond current standard of 24 to 48 hours

In a finding that may potentially improve survival from war injuries and disasters, laboratory researchers report that refrigerated whole blood may have a shelf life well beyond the current standard of 24 to 48 hours.

24 Feb 2011

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Tarix Pharmaceuticals today announced enrollment of the first patient in a Phase 2 clinical study of TXA127, a pharmaceutical grade formulation of a naturally occurring peptide known to stimulate early hematopoietic precursor cells in the bone marrow.

24 Feb 2011

Dual lab tests accurately predict vein graft blood clots in patients during CABG

A team of heart experts at Johns Hopkins has found that dual lab tests of blood clotting factors accurately predict the patients whose blood vessels, in particular veins implanted to restore blood flow to the heart during coronary artery bypass grafting, are more likely to fail or become clogged within six months.

23 Feb 2011

MD Anderson physician honored for impact on blood, marrow transplantation

The American Society for Blood and Marrow Transplantation has honored leader, innovator and educator Richard Champlin, M.D., with its Lifetime Achievement Award during the group's annual meeting Feb. 17-21.

23 Feb 2011

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Genzyme Corporation today announced three-year follow-up data from patients enrolled in the phase 2 clinical trial for its investigational oral therapy for Gaucher disease type 1 known as eliglustat tartrate. Sustained or further improvements were observed across all endpoints, including bone disease, at the three-year timepoint.

19 Feb 2011

Platelet-rich fibrin matrix doesn't improve healing after rotator cuff repair

For years, doctors have used platelet rich plasma (PRP) to promote healing in various surgeries, but a recent study demonstrates that a type of PRP did not improve healing after rotator cuff repair.

18 Feb 2011

TI Pharma launches new research project on stem cell transplant

Top Institute Pharma is today launching a new research project that should make stem cell transplants more successful. A stem cell transplant is usually performed on adults with acute leukemia.

18 Feb 2011

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

miRagen Therapeutics, Inc., a privately-held biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to the company's compound MGN-4893 for the treatment of polycythemia vera, a myeloproliferative disease characterized by an overabundance of blood cells and platelets in the body.

18 Feb 2011

NYBC ends emergency appeal for blood donations

Thanks to the support of blood donors – who answered the emergency call after winter snowstorms drove blood supplies to critical levels – New York Blood Center is ending its emergency appeal for blood donations and returning to its normal collection schedule. The supply of several blood types, including O-negative blood, has returned to recommended 3-5 day inventory levels.

10 Feb 2011

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

Arteriocyte, a leading clinical stage biotechnology company with offices in Cleveland, Ohio and Hopkinton, Massachusetts that develops proprietary stem cell and tissue engineering based therapies, announced today approval from the Food and Drug Administration to initiate a Phase I clinical trial using its Magellan MAR01 technology in the treatment of Critical Limb Ischemia.

29 Jan 2011

American Red Cross urges all eligible donors to donate blood

Severe winter weather throughout much of the eastern half of the United States in recent weeks has already caused the cancellation of more than 14,000 blood and platelet donations through the American Red Cross. With more winter weather and a possible coastal storm predicted, the Red Cross is urging all eligible blood donors to help boost its blood supply back up to sufficient levels.

25 Jan 2011

SuppreMol completes successful pre-IND meeting with U.S. FDA

SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases, today announced that it has successfully completed a pre-Investigational New Drug Application (pre-IND) meeting with the U.S. Food and Drug Administration (FDA) for its lead compound SM101, which is being developed for the treatment of Primary Immune Thrombocytopenia (ITP) and Systemic Lupus Erythematosus (SLE).

24 Jan 2011

Platelets News and Research

Clinical trial to evaluate efficacy of PRP for osteoarthritis pain treatment

Major breakthrough in thrombosis

Tiniest pollution particles can contribute to cardiovascular disease in diabetic people

Wound Repair and Regeneration publishes positive findings from CXM's Matrix Phase 2b clinical study

Study reveals expansion of NK cells after acute infection

Oxygen Biotherapeutics receives U.S. Army grant for studies of Oxycyte

U.S. Army awards Oxygen Biotherapeutics two-year grant to study Oxycyte PFC emulsion against TBI

PAH closely related to bone marrow abnormalities

Refrigerated whole blood may have shelf life beyond current standard of 24 to 48 hours

First patient enrolled in TXA127 Phase 2 clinical study to stimulate engraftment following transplant

Dual lab tests accurately predict vein graft blood clots in patients during CABG

MD Anderson physician honored for impact on blood, marrow transplantation

Genzyme reports 3-year follow-up data from eliglustat tartrate Phase 2 trial for Gaucher disease

Platelet-rich fibrin matrix doesn't improve healing after rotator cuff repair

TI Pharma launches new research project on stem cell transplant

FDA grants miRagen's MGN-4893 orphan drug designation for treatment of polycythemia vera

NYBC ends emergency appeal for blood donations

FDA approves Arteriocyte's Magellan MAR01 technology for Phase I trial to treat CLI

American Red Cross urges all eligible donors to donate blood

SuppreMol completes successful pre-IND meeting with U.S. FDA

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News